Warren L.Nachlis Ph.D.

Partner

New York + 1.212.326.8364 Boston + 1.617.449.6941

Collegati

Condividi

Warren Nachlis focuses on licensing and technology transactional matters for clients worldwide.

His practice includes a wide range of intellectual property-related matters, including licensing, joint ventures, joint development agreements, sponsored research agreements with academic and nonprofit organizations, development and supply agreements, technology issues, and strategic intellectual property counseling. Warren also routinely advises clients on intellectual property issues that arise in connection with larger corporate transactions such as mergers and acquisitions, capital markets offerings, secured lending transactions, asset securitizations, and private equity investments.

Warren has experience in a broad spectrum of technology areas with particular emphasis in the pharmaceutical, biotechnology, medical device, electronics, media, entertainment, and financial information industries. His representative clients include Astellas, Astra Zeneca, Celgene, City of Hope, Essilor, Kyowa Kirin, REGENXBIO, Sanofi, SAP, Verint Systems, and Visible Alpha. In addition, Warren's experience includes patent litigation and interference matters, and he has a strong technical background in polymers, pharmaceuticals, chemistry, and biology.

Warren is a member of the Licensing Committee of the Intellectual Property Owners Association.

Esperienze

  • Sanofi, Orano Med, and RadioMedix collaborate to develop radioligand therapiesJones Day represented and supported Sanofi's in-house team in connection with an exclusive licensing agreement with RadioMedix, Inc., and Orano Med, a subsidiary of the Orano Group.
  • Amolyt Pharma acquired by AstraZenecaJones Day advised Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, in its $1.05 billion acquisition by AstraZeneca.
  • Astellas enters into strategic collaboration and license agreement with Kelonia Therapeutics to develop novel immuno-oncology therapeuticsJones Day represented Xyphos Biosciences, Inc. (a wholly-owned subsidiary of Astellas Pharma Inc.) in connection with a research collaboration and license agreement with Kelonia Therapeutics, Inc. ("Kelonia"), a biotech company pioneering new genetic medicines using its in vivo gene placement system (iGPS®).
  • Sanofi and Janssen collaborate to develop vaccines for extra-intestinal pathogenic E. coliJones Day represented and supported Sanofi's in-house team in its strategic collaboration with Janssen Pharmaceuticals, now "Johnson & Johnson Innovative Medicine," in connection with a Co-Development, Co-Commercialization & License Agreement with Johnson & Johnson's Janssen Pharmaceuticals relating to the development and commercialization of vaccines for extra-intestinal pathogenic E. coli.
  • Sumitomo acquires assets and rights related to lefamulin from NabrivaJones Day advised Sumitomo Pharma Co., Ltd. in the acquisition of assets from Nabriva Therapeutics plc and various wholly-owned subsidiaries. This acquisition includes assets from the U.S., Ireland, and Austria in support of the development, manufacture, marketing and commercialization of lefamulin in the People’s Republic of China, Hong Kong, Macau and Taiwan.
  • Astellas acquires Iveric bioJones Day advised Astellas Pharma Inc. in the $5.9 billion cash acquisition of Iveric bio, Inc., a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.
  • Astellas enters into strategic collaboration and exclusive option license agreement with ImmunoPrecise Antibodies Ltd.Jones Day represented Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas Pharma Inc., "Astellas") in connection with a research collaboration and exclusive option license agreement with ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company.
  • Astellas enters into collaboration and exclusive license agreement with GenerianJones Day advised Astellas Pharma Inc. and its affiliate Mitobridge, Inc. in connection with a collaboration and exclusive license agreement with Generian Pharmaceuticals, Inc. to discover and develop novel small molecules for undruggable therapeutic targets.
  • Goode Partners invests in JOCKO FUELJones Day advised Goode Partners LLC in its $30 million minority investment in JOCKO FUEL, a disruptive and rapidly-growing provider of premium sports and lifestyle nutritional products.
  • Delaware North launches Gamewise joint venture partnership for sports betting and iGamingJones Day advised Delaware North in the formation of a joint venture with leading Belgian gaming and sports betting partner, GAMING1, for sports betting and iGaming.
  • Signature Aviation sells Global Engine Services business to StandardAero for $230 millionJones Day advised Signature Aviation plc, a market-leading provider of global aviation support services, in the $230 million sale of the Engine Repair and Overhaul (ERO) business to StandardAero, a portfolio company owned by The Carlyle Group and a leading provider of maintenance, repair, and overhaul services.
  • Delaware North sells Jumer’s Casino & Hotel to Bally's for $120 millionJones Day advised Delaware North, a global hospitality and entertainment company with operations in the sports, travel hospitality, restaurant and catering, lodging, gaming and specialty retail industries, in the sale of Jumer’s Casino & Hotel in Rock Island, Illinois, to Bally's Corporation for $120 million in cash.
  • Astellas returns rights to Eligard® in Europe, Middle East, CIS, and Asia to TolmarJones Day represented Astellas Pharma Europe Ltd. in connection with a series of transactions, including the sale of related assets, in which Astellas returned its in-licensing rights to Eligard® (leuprorelin acetate for injectable suspension), a treatment for advanced prostate cancer, sold by Astellas in Europe, the Middle East, the Commonwealth of Independent States (CIS) and Asia, to Tolmar International Limited.
  • Astellas Pharma acquires iota BiosciencesJones Day advised Astellas Pharma Inc. in its acquisition of iota Biosciences.
  • Hard Rock International acquires full intellectual property rights to Hard Rock Hotel & Casino® in Las Vegas in deal with Juniper CapitalJones Day advised Hard Rock International in its acquisition of all rights to the Hard Rock® brand and related trademarks in Las Vegas from private equity firm Juniper Capital.
  • VSE Corporation divests Prime Turbines, LLC to PTB Holdings USA, LLCJones Day advised VSE Corporation, a leading provider of distribution and repair services for land, sea, and air transportation assets in the public and private sectors, in the sale of subsidiary Prime Turbines, LLC to PTB Holdings USA, LLC.
  • BBA Aviation sells Ontic for $1.365 billionJones Day advised BBA Aviation plc ("BBA") in the sale of its Ontic business to an investment fund affiliated with CVC Capital Partners for $1.365 billion.
  • Hard Rock International acquires JACK Cincinnati Casino and Turfway Park for $745 millionJones Day advised Hard Rock International on the acquisition of JACK Cincinnati Casino, located in downtown Cincinnati, Ohio, together with VICI Properties, Inc., and Turfway Park, located in Florence, Kentucky, for an aggregate purchase price of approximately $745 million in cash.
  • Finacity Corporation acquired by Greensill CapitalJones Day advised Finacity Corporation, a leader in specialized receivables securitization, in its acquisition by Greensill Capital, the leading non-bank provider of working capital finance for companies globally.
  • Engage PEO acquired by Lightyear CapitalJones Day advised Engage PEO, a professional employer organization providing HR outsourcing solutions to small and mid-sized businesses across the U.S., in its acquisition by Lightyear Capital.
    •

    January 2017 Alert

    Antitrust Alert: U.S. Agencies Issue New Antitrust Guidelines for Intellectual Property Licensing

    September 2016 Alert

    Antitrust Alert: U.S. Agencies Propose New Antitrust Guidelines for Intellectual Property Licensing

    November 2013 Alert

    Antitrust Alert: FTC Expands Premerger Notification Requirements to Cover Certain Pharmaceutical Patent Licenses

    • March 2015
      BIO Conference on International Taxation in the Biopharmaceutical Industry
    • November 13, 2013
      2013-2014 Life Sciences Webinar Series: Intellectual Property, Regulatory, and Antitrust Issues in Life Sciences M&A and Capital Markets Transactions

    Prima di procedere all'invio, si prega di notare:

    il contenuto del presente sito web è a scopo esclusivamente informativo e non può essere considerato un parere legale o altro tipo di consulenza professionale. L'invio o la ricezione della presente email non è atta ad instaurare alcun rapporto cliente/avvocato. Le informazioni inviate tramite questa funzione al nostro Studio non saranno coperte da vincolo di riservatezza o confidenzialità fintanto che non ci sia stato conferito e non sia stato da noi accettato un incarico professionale. Inviando il messaggio confermate di aver preso visione e accettato il contenuto di questa informativa.